
Denis Chem Lab (DENISCHEM) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Mar 2025Income Metrics
Revenue
413.8M
Gross Profit
186.4M
45.03%
Operating Income
3.2M
0.78%
Net Income
7.1M
1.71%
Balance Sheet Metrics
Total Assets
1.1B
Total Liabilities
271.7M
Shareholders Equity
851.0M
Debt to Equity
0.32
Cash Flow Metrics
Revenue & Profitability Trend
Denis Chem Lab Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 1.7B | 1.7B | 1.6B | 1.4B | 1.1B |
Cost of Goods Sold | 957.7M | 868.6M | 844.6M | 742.2M | 573.0M |
Gross Profit | 775.3M | 809.6M | 763.9M | 622.7M | 518.5M |
Gross Margin % | 44.7% | 48.2% | 47.5% | 45.6% | 47.5% |
Operating Expenses | |||||
Research & Development | - | - | - | - | - |
Selling, General & Administrative | - | - | 152.3M | 139.2M | 121.6M |
Other Operating Expenses | 461.6M | 453.4M | 445.8M | 190.4M | 155.7M |
Total Operating Expenses | 461.6M | 453.4M | 598.1M | 329.6M | 277.3M |
Operating Income | 92.5M | 142.9M | 109.6M | 116.6M | 76.5M |
Operating Margin % | 5.3% | 8.5% | 6.8% | 8.5% | 7.0% |
Non-Operating Items | |||||
Interest Income | - | - | 4.7M | 1.9M | 1.8M |
Interest Expense | 5.1M | 5.4M | 6.4M | 5.0M | 12.0M |
Other Non-Operating Income | - | - | - | - | - |
Pre-tax Income | 111.1M | 151.3M | 109.2M | 88.8M | 30.9M |
Income Tax | 30.4M | 39.8M | 30.6M | 26.2M | 8.2M |
Effective Tax Rate % | 27.3% | 26.3% | 28.0% | 29.5% | 26.7% |
Net Income | 80.8M | 111.6M | 78.6M | 62.6M | 22.6M |
Net Margin % | 4.7% | 6.6% | 4.9% | 4.6% | 2.1% |
Key Metrics | |||||
EBITDA | 184.8M | 226.2M | 193.7M | 173.4M | 134.1M |
EPS (Basic) | - | ₹8.04 | ₹5.66 | ₹4.51 | ₹1.63 |
EPS (Diluted) | - | ₹8.04 | ₹5.66 | ₹4.51 | ₹1.63 |
Basic Shares Outstanding | - | 13875373 | 13886572 | 13876668 | 13876668 |
Diluted Shares Outstanding | - | 13875373 | 13886572 | 13876668 | 13876668 |
Income Statement Trend
Denis Chem Lab Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 8.5M | 11.9M | 24.8M | 13.0M | 15.7M |
Short-term Investments | 270.3M | 246.0M | 144.0M | 65.8M | 11.3M |
Accounts Receivable | 306.1M | 316.6M | 312.4M | 318.4M | 328.8M |
Inventory | 98.1M | 101.9M | 91.2M | 98.9M | 91.1M |
Other Current Assets | 23.4M | 17.3M | 263.0K | 20.7M | 13.2M |
Total Current Assets | 706.4M | 693.7M | 592.4M | 533.2M | 485.5M |
Non-Current Assets | |||||
Property, Plant & Equipment | 387.2M | 374.4M | 37.9M | 37.7M | 37.7M |
Goodwill | 1.1M | 1.8M | 2.2M | 2.8M | 1.4M |
Intangible Assets | 1.1M | 1.8M | 2.2M | 2.8M | 1.4M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 3.9M | 6.8M | 10.0M | - | 5.3M |
Total Non-Current Assets | 416.3M | 399.8M | 402.1M | 430.7M | 437.1M |
Total Assets | 1.1B | 1.1B | 994.5M | 963.9M | 922.6M |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 212.4M | 214.1M | 182.8M | 197.0M | 156.7M |
Short-term Debt | 3.7M | 5.9M | 10.1M | 10.4M | 51.2M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 7.7M | 4.0M | 2.1M | 2.8M | 1.3M |
Total Current Liabilities | 261.7M | 272.0M | 240.8M | 253.1M | 251.0M |
Non-Current Liabilities | |||||
Long-term Debt | 4.5M | 4.5M | 9.2M | 21.8M | 35.0M |
Deferred Tax Liabilities | 0 | 9.6M | 19.4M | 18.6M | 8.3M |
Other Non-Current Liabilities | - | - | - | -1.0K | 2 |
Total Non-Current Liabilities | 10.0M | 17.9M | 31.1M | 46.3M | 56.6M |
Total Liabilities | 271.7M | 289.8M | 271.8M | 299.4M | 307.6M |
Equity | |||||
Common Stock | 138.8M | 138.8M | 138.8M | 138.8M | 138.8M |
Retained Earnings | - | - | 261.9M | 203.8M | 154.3M |
Treasury Stock | - | - | - | - | - |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 851.0M | 803.7M | 722.6M | 664.5M | 615.0M |
Key Metrics | |||||
Total Debt | 8.2M | 10.5M | 19.3M | 32.2M | 86.2M |
Working Capital | 444.7M | 421.8M | 351.6M | 280.1M | 234.6M |
Balance Sheet Composition
Denis Chem Lab Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 111.1M | 151.3M | 109.2M | 88.8M | 30.9M |
Depreciation & Amortization | - | - | - | - | - |
Stock-Based Compensation | - | - | - | - | - |
Working Capital Changes | 7.2M | -27.6M | 19.6M | 1.1M | 10.3M |
Operating Cash Flow | 105.0M | 116.4M | 130.6M | 95.6M | 54.9M |
Investing Activities | |||||
Capital Expenditures | - | - | - | - | - |
Acquisitions | - | - | - | - | - |
Investment Purchases | - | - | - | - | - |
Investment Sales | - | - | - | - | - |
Investing Cash Flow | - | - | -69.2M | 1.1M | 1.0M |
Financing Activities | |||||
Share Repurchases | - | - | - | - | - |
Dividends Paid | -34.7M | -27.8M | -20.8M | -10.4M | - |
Debt Issuance | - | - | - | - | - |
Debt Repayment | - | - | -12.8M | -54.0M | -39.5M |
Financing Cash Flow | -37.0M | -31.9M | -33.9M | -105.2M | -76.0M |
Free Cash Flow | 44.6M | 106.8M | 116.4M | 115.8M | 61.3M |
Net Change in Cash | 68.0M | 84.4M | 27.4M | -8.5M | -20.1M |
Cash Flow Trend
Denis Chem Lab Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
16.44
Price to Sales
0.77
Profitability Ratios
Profit Margin
44.74%
Operating Margin
6.71%
Return on Equity
9.49%
Return on Assets
7.19%
Financial Health
Current Ratio
2.70
Debt to Equity
0.01
Per Share Data
EPS (TTM)
₹5.82
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
denischem | 1.3B | 16.44 | - | 9.49% | 44.74% | 0.01 |
Sun Pharmaceutical | 3.9T | 37.88 | 5.45 | 15.08% | 19.29% | 3.26 |
Divi's Laboratories | 1.6T | 70.79 | 10.93 | 14.64% | 23.89% | 0.03 |
Sun Pharma Advanced | 45.5B | -13.34 | -21.04 | 157.88% | -53.22% | -1.24 |
Aarti Drugs | 44.8B | 23.75 | 3.28 | 12.28% | 7.80% | 44.92 |
Sequent Scientific | 43.9B | 154.18 | 6.24 | 2.84% | 1.85% | 62.47 |
Financial data is updated regularly. All figures are in the company's reporting currency.